<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Paris_Bettencourt_Human_Practices skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Paris Bettencourt/Human Practices</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="col-md-8"><UL class=" text-left wtf-menu "><LI class="parent main-item"><A href="#">Project  </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Human_Practices">Human Practices</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Applied_Design">Applied Design</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Design">Design</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Production">Production</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Active_Testing">Testing </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Active_Testing">Active Testing</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Biocompatibility_Testing">Biocompatibility Testing</A></LI></UL><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Model">Modeling</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Optimization">Optimization</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Public_Engagement">Public Engagement</A></LI><LI class="parent main-item"><A href="https://2018.igem.org/Team:Paris_Bettencourt/Software">Software  </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/AMPDesigner_Overview">AMP Designer Overview</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/AMP_Forest">AMP Forest</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/AMP_Evolver">AMP Evolver</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Result">Result</A></LI><LI class="parent main-item"><A href="#">Judging </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Medal_Criteria">Medal Criteria </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Results">Key Results</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/BioBricks">BioBricks</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/InterLab">InterLab</A></LI><LI class="parent main-item"><A href="#">Team  </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Members">Members</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Collaborations">Collaborations</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Attributions">Attributions</A></LI><LI class="parent main-item"><A href="https://2018.igem.org/Team:Paris_Bettencourt/Lab_Notebook">Lab Notebook</A></LI><LI class="parent main-item"><A href="https://2018.igem.org/Team:Paris_Bettencourt/Acknowledgements">Acknowledgements</A></LI><DIV id="logolist2"><DIV class="sidelogos top5"><DIV id="twitapp"><A class="twitter-timeline" width="250" height="400" data-dnt="true" href="https://twitter.com/iGEM_Paris" data-widget-id="368144501119795201">@iGEM_Paris</A></DIV></DIV></DIV></DIV><DIV class="textbody h1"><H1>Human Practices - Integrated Design</H1></DIV><DIV class="textbody h2"><H2 id="Introduction">Introduction</H2></DIV><DIV class="textbody"><P>We are a group of diverse talents coming from different fields aiming to solve one of the world’s current challenges through synthetic biology. This year, we are tackling the global threat of <B>antimicrobial resistance</B>. With the increase in the number of multidrug-resistant bacteria, antimicrobial resistance is one of the public health threats we face today.
</P></DIV><DIV class="textbody"><P>Antibiotic overuse in<B> livestock industry </B>is one of the major drivers to the antibiotic resistance evolution — motivating calls to reduce, replace, and re-think the antibiotic usage in animals. <B>Antimicrobial peptides (AMPs)</B> are a promising alternative to conventional antibiotics. Recently, a class of chemically-synthesized, star-shaped AMPs has been shown to exhibit broad-spectrum antimicrobial activity while maintaining biocompatibility with mammalian cells. 
</P></DIV><DIV class="textbody"><P> As we design our work in constructing <B>StarCores</B>, we stumbled upon essential questions such as, what type of AMP to use that will yield into a stable protein structure conformation? More importantly, what antibiotics do we need to replace, particularly in the livestock industry? In order to narrow down our broad concept, we did literature search and reached out to the people who are involved in this line of work such as veterinarians and farmers.</P></DIV><DIV class="textbody"><P>Without further ado, the <B>integrated human practice section</B> tells the  wonderful story of how we went from simple, monomeric AMPs into a  nontoxic, multimeric StarCores aiming to treat gastrointestinal infection in piglet caused by Gram-negative bacteria.</P></DIV><DIV class="textbody h2"><H2>Results</H2></DIV><DIV class="textbody h3"><H3><B>France has a robust policy to reduce antibiotic resistance</B></H3></DIV><DIV class="textbody"><P>Since 2001, France has implemented a series of policies to combat the rise of antibiotic resistance. The overall goals could be summarized as follows:</P></DIV><DIV class="textbody"><LI>To “reduce, replace and re-think” the use of antibiotics in humans and animals.</LI><LI>To raise awareness of the problem among doctors, veterinarians and the public.</LI><LI>To coordinate policy with other countries under the slogan “One World, One Health.”</LI></DIV><DIV class="textbody"><P>We studied these policies, using them to frame our own research. From this, we learned about ECOANTIBIO, a national plan created by the Ministry of Health to reduce antibiotic use in livestock by 25% over five years. This program is coordinated with similar efforts to reduce antibiotic use in humans, with the knowledge that antibiotic resistance can pass easily from animal to human pathogens.</P><P>The policy goal to raise awareness was successful in France. Thanks to our study of the existing French policy, we realized that the veterinary sector was a major priority.</P></DIV><DIV class="textbody h3"><H3><B>Veterinarians confront antibiotic resistance in pigs</B></H3></DIV><DIV class="textbody"><P>We reached out to our personal networks to find people on the front lines of antibiotic resistance. We traveled to Brittany, a major center of French meat production, and met with:</P></DIV><DIV class="textbody"><LI><EM>Marc Quere</EM>, a retired veterinarian and writer.</LI><LI><EM>Paul Pfister</EM>, the CEO of a large veterinary practice.</LI><LI><EM>Benoît Quéro</EM>, a vet and the mayor of Plumeliau, a farming town.</LI></DIV><DIV class="textbody"><P>From these veterinarians, we learned of the real-world challenges of treating antibiotics in piglets. Pork represents 46% of the meat consumed in France, making the pig industry a major consumer of antibiotics.</P></DIV><DIV class="textbody"><P>Piglets in particular are sensitive to digestive disease and easily die from them, so farmers treat infections aggressively. We decided to target piglet intestinal infections for our application.</P></DIV><DIV class="textbody h3"><H3><B>The importance of <I>E. coli</I> and other Gram-negatives</B></H3></DIV><DIV class="textbody"><P>Once we had decided to focus on pig intestine infections,  we wanted more specific data about the pathogens and resistances at work. We attended the conference “Antimicrobial Resistance and Society” at the Institut Curie. There we met Jean-Yves Madec, scientific director of ANSES, the national food security agency.</P><P> He confirmed for us that piglet gut infections are a major concern and that E. coli and other Gram-negative pathogens are the most common cause.</P></DIV><DIV class="textbody"><P>With his help, we obtained access to raw data from PORC 2017, a surveillance program for antibiotic resistance in animals. These data highlight amoxicillin and tetracycline as drugs with the most frequent evolved resistance. With this information, we knew which bacterial species we needed to target and which drugs we needed to replace.</P></DIV><DIV class="textbody"><P>Table 1: <I>E. coli</I> sensitivity to several families of antibiotics from French pigs of farms in Brittany.<I> E. coli</I> appears to be the least sensitive towards Tetracyclin. The colours indicate the types of antibiotics.</P></DIV><DIV class="textbody h2"><H2>Publishing our Work in The Conversation</H2></DIV><DIV class="textbody"><P>Our research into the problem of antibiotic resistance brought us into contact with farmers, doctors, researchers and policy professionals all over France. Along the way, we befriended many good people from different domains, united by a common goal. We had even obtained an original, unpublished data set to study and analyze.</P><P>Thinking back to the original policy goals that motivated us, one of them was raising awareness and informing the public. We contacted The Conversation, a news magazine that specializes in making academic research accessible to the public. With help from their journalists and editors, our study of antibiotic resistance in France was published in both French and English.</P></DIV><DIV class="textbody"><P>Article :
<A href="https://theconversation.com/porcelet-bacteries-et-antibioresistance-un-trio-dangereux-pour-la-sante-humaine-104723"> Piglets, bacteria and antibiotic resistance: a dangerous combination for human health</A><A href="https://static.igem.org/mediawiki/2018/6/66/T--Paris_Bettencourt--Article-Piglets-Bacteria-Antibiotic-Resistance-TheConversation.pdf" target="_blank">PDF</A></P></DIV><DIV class="textbody h2"><H2>Integrated Design</H2></DIV><DIV class="textbody"><P>Our work in Integrated Design lead us to the key features needed for our antibiotic replacement.</P></DIV><DIV class="textbody"><LI>An antimicrobial peptide</LI><LI>to replace amoxicillin and tetracycline</LI><LI>for killing Gram-negative E.coli</LI><LI>in the piglet intestine</LI><LI>with low toxicity to mammalian cells</LI></DIV><DIV id="footerdiv"><DIV id="mfooter"><DIV class="footbox"><B>Centre for Research and Interdisciplinarity (CRI)</B>
    Faculty of Medicine Cochin Port-Royal, South wing, 2nd floor
    Paris Descartes University
    24, rue du Faubourg Saint Jacques
    75014 Paris, France<A href="mailto:paris-bettencourt-2018@cri-paris.org">paris-bettencourt-2018@cri-paris.org</A></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>